

THESIS OUTLINE

Exploring metabolically compromised secretome and bioactives on islet differentiation and function for effective diabetic therapy

Thesis Abstract

Chapter 1. Introduction and Review of Literature

Chapter 2. Aims & Objectives

Chapter 3. Identification of molecular targets of swertisin in glucose homeostasis and islet differentiation & functionality

Chapter 4. Effect of secretome of skeletal muscle on islet differentiation & functionality

Chapter 5. Effect of secretome of adipose derived stem cells on islet differentiation & functionality

Chapter 6. Summary and Conclusion

Table of contents

Abstract.....	1
Chapter 1. Introduction & Review of Literature.....	5
1. The Pancreas	5
1.1. Types of Endocrine Cells	6
i) α -cells	6
ii) β -Cells	7
iii) Delta-Cells	10
iv) PP Cells	10
v) Epsilon Cells	10
1.2 Pancreatic Islet Cell Development	11
1.3 Transcriptional regulation of islet development in the pancreas.....	12
A) HNF-3B	13
B) Pdx1	13
C) NESTIN	13
D) Ngn3	14
E) Pax4	14
F) Nkx6.1	14
G) NeuroD	15
H) MafA.....	15
I) GLUT2	15
2. Diabetes Mellitus.....	16
2.1 Epidemiology	16
2.2 Classification of Diabetes.....	17
Type 1 Diabetes Mellitus	17

A)	Symptoms.....	18
B)	Diagnosis.....	18
C)	Etiology of T1DM.....	19
i.	Genetic	20
ii.	Environmental	21
iii	Chemicals and Drugs	22
D)	Type 1 Diabetes Management.....	22
i.	Diabetic diet and lifestyle modification	22
ii.	Insulin therapy.....	23
	Types of Insulin	23
iii.	Cell replacement therapies.....	24
	1. Pancreas Transplantation	24
	2. Islet Transplantation.....	24
	3. Islet neogenesis	25
	□ Sources of islet neogenesis	26
	A) Embryonic stem cells (ESC)	26
	B) Induced pluripotent stem cells (iPSC).....	26
	C) Adult stem cells.....	27
	D) Pancreatic progenitors cells.....	29
	□ Induction of differentiation of Stem/Progenitors cells into islets by chemical compounds	30
	□ Induction of islet neogenesis by medicinal plants	31
	□ Enicostemma littorale: Anti diabetic effects and islet neogenesis.....	32
	□ Induction of islet neogenesis by bioactive molecules	33
		35

Type 2 Diabetes Mellitus	36
Insulin and its target organs	36
Insulin signaling	37
Insulin Resistance.....	38
Manifestation sites for insulin resistance.....	39
A) Skeletal muscle.....	39
i. Molecular mechanism of insulin resistance	40
B) Adipose tissue	41
i. Adipose derived stem cells	41
Insulin resistance at the systemic level.....	43
Interorgan crosstalk and its impact in normal and diabetic condition.....	43
i. Skeletal muscle as a secretory organ and its effect on pancreas/islets	43
ii. ADSC Secretome and its effect on pancreas/islets	46
Type 2 Diabetes Mellitus Management	47
i. Insulin sensitizers	48
A) Biguanides.....	48
B) Thiazolidinediones	49
ii. Insulin secretagogues	49
A) Sulfonylureas	49
iii. Alpha-glucosidase inhibitors	50
iv. Incretin mimetics	50
v. Dipeptidyl peptidase-4 inhibitor	51
vi. Glycosurics	51
A) Classification of SGLT	51
B) Mechanism of SGLT.....	52

C)	The action of SGLT inhibitors.....	53
D)	Regulation of SGLT2.....	55
i.	Commercially available SGLT2 inhibitors.....	55
ii.	Natural compounds as SGLT2 inhibitors	57
Chapter 2.	Aims and Objectives.....	60
Chapter 3:	Identification of molecular targets of Swertisin in glucose homeostasis, islet differentiation & functionality	63
3.1	Introduction.....	63
3.2	Materials and Methods	64
3.2.1	<i>In silico</i> molecular target identification of swertisin in glucose lowering effect	64
A.	<i>In silico</i> pharmacokinetic study of swertisin	64
B.	<i>In silico</i> target prediction of swertisin	64
C.	Homology modeling and preparation of human SGLT2 protein structure.....	65
D.	Structure Validation of the Human SGLT2 (hSGLT2) model	66
E.	Molecular docking of hSGLT2 with swertisin.....	66
F.	Molecular dynamics simulation of hSGLT2 and hSGLT2 docked complexes.....	68
G.	Binding free energy estimation of SGLT2 with swertisin and canagliflozin complexes .	69
3.2.2	<i>In vitro</i> studies	69
A.	Chemicals	69
B.	Cell culture.....	69
C.	Sodium dependent glucose uptake assay	69
3.2.3	Protein extraction and western blotting.....	71
3.2.4	<i>In vivo</i> studies.....	71
	Animal selection and induction of diabetes and <i>in vivo</i> experimental design	71
3.2.5	Immunohistochemistry.....	73

3.2.6 H&E (Haematoxylin and eosin) staining	73
3.2.7 Statistical analysis	73
3.3 RESULTS.....	74
3.3.1 <i>In silico</i>	74
A. Pharmacokinetic analysis of swertisin	74
B. Molecular target prediction of swertisin	82
C. Molecular docking of hSGLT2 with swertisin	88
D. Molecular dynamics simulations	93
E. Stability of SGLT2 and SGLT2 with swertisin and canagliflozin.....	93
F. Residue-wise fluctuation and radius of gyration of SGLT2 and SGLT2 with swertisin and canagliflozin	93
G. Molecular interaction through hydrogen bonding.....	96
H. Difference in interactions network of SGLT2 and SGLT2 with swertisin and canagliflozin complexes through dynamics cross-correlation matrix (DCCM):	97
I. Principal Component Analysis (PCA)	100
J. Binding free energy estimation and energy decomposition of SGLT2 complexes with canagliflozin and swertisin:.....	101
3.3.2 <i>In vitro</i> molecular target identification of swertisin for glucose lowering effect	104
A. Swertisin suppresses sodium dependent glucose uptake by selectively inhibiting SGLT2	104
B. Swertisin regulates key SGLT2 related proteins	107
3.3.3 <i>In vivo</i> molecular target identification of swertisin in glucose lowering effect	110
A. Swertisin improves glycaemic control in STZ induced diabetic mice: an <i>in vivo</i> study....	110
B. Swertisin affects physiological and metabolic parameters in STZ induced diabetic mice	111
C. Swertisin reduces expression of SGLT2 along with inhibition in kidney tissue of mice...	116
3.4 Discussion.....	120
3.5 Summary.....	125

Chapter 4: Effect of secretome of skeletal muscle on islet differentiation & functionality	130
4.1 Introduction.....	130
4.2 Material and Methods and Experimental Design.....	131
4.3 RESULTS.....	135
4.3.1 Formation and confirmation of C2C12 myogenic differentiation into myotubes.....	135
4.3.2 TNF- α induced insulin resistance in C2C12 myotubes.....	138
4.3.3 Insulin resistance affects the myokine profiling from C2C12 myotubes.....	140
4.3.4 Protein characterization from the secretome of control and IR C2C12 myotube	142
4.3.5 ILCCs from PREPs demonstrates compromised functional and phenotypic characterization under IR C2C12 myotube secretome.....	145
4.3.6 ILCCs from PREPs under IR C2C12 myotube secretome demonstrate low islet cell survival and integrity.....	149
4.3.7 ILCCs from PREPs under control C2C12 myotube secretome demonstrates high fidelity towards differentiation	152
4.4 Discussion.....	154
4.5 Summary.....	160
Chapter 5: Effect of secretome of adipose derived stem cells on islet differentiation & functionality	163
5.1 Introduction.....	163
5.2 Material and Methods.....	164
5.2.1 Cell culture	164
5.2.4 High-performance liquid chromatography of Conditioned media (CM) of hADSC	166
5.3 RESULTS.....	167
5.3.1 Characterization of proteins of hADSC secretome from control and obese	167
5.3.2 ILCCs from PREPs under control hADSC secretome demonstrates optimal functional and phenotypic characterization.....	173

5.3.3 ILCCs from PREPs under control hADSC secretome demonstrates high islet cell survival and integrity.....	176
5.3.4 ILCCs from PREPs under control hADSC secretome demonstrates high fidelity towards differentiation.....	179
5.4 Discussion.....	182
5.5 Summary.....	187
Chapter 6: Summary and Conclusions	191
Chapter 7: References.....	197
Appendix	
List of Figures.....	245
List of Tables	252
List of primers.....	253
List of Antibodies.....	254
Publications.....	257
Oral/Poster presentations	
Synopsis	